We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Leica Biosystems Launches HistoCore PEGASUS Plus Dual-Retort Tissue Processor in Europe

By LabMedica International staff writers
Posted on 04 May 2022

Leica Biosystems (Nussloch, Germany) has launched a compact, dual-retort tissue processor, the HistoCore PEGASUS Plus. More...

For the first time, the technology will now be available to medium-sized laboratories, enabling them to optimize histopathology workflows.

Mid-sized laboratories will now be able to run multiple protocols in parallel on a single instrument, providing a solution that adapts to their workflow needs, and reduces unnecessary hands-on time. The dual retorts on HistoCore PEGASUS Plus increase capacity by 33% compared to a typical 300-cassette single-retort tissue processor. The HistoCore PEGASUS Plus builds on more than 15 years of experience with the larger HistoCore PELORIS system, and also incorporates Leica’s pioneering integrated track and trace technology, the HistoCore I-Scan. This enables laboratories to capture and store individual cassette information, user interactions, and reagent levels, delivering high confidence in the quality of results.

Labs face problems with tissue processing, creating the need for a solution to under- or over-processing. This occurs when labs have to process both biopsy and large routine tissue specimens in the same processing run. In an ideal scenario, biopsy and larger sample tissues would be processed separately using a protocol specific to the specimen. The HistoCore PEGASUS Plus tissue processor addresses this issue by bringing a scalable workflow solution to all labs of all sizes, ensuring optimal conditions for each tissue type without slowing down the lab. The HistoCore PEGASUS Plus is now available in Europe and where the CE mark is accepted for country-specific registration.

“We understand that labs are under pressure of staff shortages, increased daily throughput, and additional complexities with processing different types and sizes of tissue,” said Christine Munz, Vice President of Core Histology at Leica Biosystems. “Large, high throughput labs have confidence in the power and robust performance of our HistoCore PELORIS tissue processing technology. The new PEGASUS PLUS now brings these benefits to mid-sized labs.”

Related Links:
Leica Biosystems 


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Online QC Software
Acusera 24•7
New
Urine Analyzer
respons® UDS100
New
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The findings point to the feasibility of a quick, noninvasive urine-based approach to support earlier decision-making in multiple psychiatric conditions (photo credit: Shutterstock)

Noninvasive Urine Test May Support Earlier Diagnosis of Psychiatric Disorders

Delays in diagnosing serious psychiatric conditions can leave patients without timely support and complicate treatment planning. For bipolar disorder, average time to diagnosis can exceed nine years, and... Read more

Molecular Diagnostics

view channel
Image: The schematic diagram links key MASLD, MASH, and MASLD-HCC molecular drivers to emerging multi‑omics biomarkers and therapeutic modalities, highlighting the current barriers in clinical translation and strategic solutions aimed at refined risk stratification and personalized medicine (Photo courtesy of ©Science China Press)

Emerging Biomarkers Advance Early Detection of MASLD and Liver Cancer Risk

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects about 30% of people worldwide and can advance to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.